Vairavan Latha 4

What Happened
Vairavan Latha, Chief Financial Officer of Arcutis Biotherapeutics (ARQT), sold 1,320 shares in an open-market transaction on February 2, 2026. The weighted average sale price was $25.50 per share for total proceeds of $33,658. The filing states the sale was to satisfy tax withholding obligations arising from the vesting of previously granted RSUs.

Key Details

• Transaction date: 2026-02-02; Form 4 filed 2026-02-04 (appears timely).
• Transaction type: Sale (open market) to cover tax withholding related to RSU vesting (footnote F1).
• Shares sold: 1,320; weighted average price reported $25.50; proceeds $33,658.
• Price range: shares sold in multiple transactions at prices from $24.745 to $25.68 (footnote F2). The reporting person will provide per-price breakdown on request.
• RSU details (per footnote F1): RSUs were granted 01/12/2024; 25% vest annually on Feb 1 beginning Feb 1, 2025, subject to continued service.
• Shares owned after transaction: not disclosed in the provided filing.

Context
This was a "sell-to-cover" transaction to meet tax withholding on vested RSUs, which is a common, administrative reason for insider sales and not necessarily a signal about the insider’s view of the company. The filer has offered to provide detailed per-trade pricing if requested by the SEC, the company, or a security holder.